➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Harvard Business School
McKinsey
Moodys

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEGRETOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Tegretol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000441 Drug Therapy for Alcohol Detoxification Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 1969-12-31 This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.
NCT00005951 Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma Completed National Cancer Institute (NCI) Phase 1 2000-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00005951 Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma Completed Duke University Phase 1 2000-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tegretol

Condition Name

Condition Name for Tegretol
Intervention Trials
Gliosarcoma 3
Epilepsy 3
Glioblastoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tegretol
Intervention Trials
Glioma 4
Gliosarcoma 3
Glioblastoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tegretol

Trials by Country

Trials by Country for Tegretol
Location Trials
United States 12
Korea, Republic of 2
Finland 1
Uruguay 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tegretol
Location Trials
North Carolina 4
Maryland 2
Virginia 1
Pennsylvania 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tegretol

Clinical Trial Phase

Clinical Trial Phase for Tegretol
Clinical Trial Phase Trials
Phase 4 7
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tegretol
Clinical Trial Phase Trials
Completed 12
Active, not recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tegretol

Sponsor Name

Sponsor Name for Tegretol
Sponsor Trials
Duke University 3
National Cancer Institute (NCI) 2
Korean Epilepsy Society 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tegretol
Sponsor Trials
Other 16
Industry 6
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
McKesson
Moodys
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.